ImmuCell (ICCC) reported late Wednesday that Q1 total sales rose more than 28% year over year to 10.4 million, driven by domestic sales and demand for its veterinary product Tri-Shield during the peak selling season.
Domestic sales for the quarter ended March 31 increased around 36% to $9.7 million.
The company said demand is now moving towards its year-round dairy customers, where it plans to acquire more clients through an expanded commercial team.
Shares of the company rose 3.8% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.